













CORRECTION



Correction to: Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia

Arnon Nagler , Christophe Peczynski , Bhagirathbhai Dholaria , Myriam Labopin , Thomas Valerius, Peter Dreger , Nicolaus Kröger, Hans Christian Reinhardt, Jürgen Finke, Georg-Nikolaus Franke , Fabio Ciceri , Mareike Verbeek, Igor Wolfgang Blau, Martin Bornhäuser, Alexandros Spyridonidis , Gesine Bug , Ali Bazarbachi , Christophe Schmid , Ibrahim Yakoub-Agha, Bipin N. Savani and Mohamad Mohty 

© The Author(s), under exclusive licence to Springer Nature Limited 2022

Bone Marrow Transplantation (2022) 57:1854; <https://doi.org/10.1038/s41409-022-01834-z>

Correction to: *Bone Marrow Transplantation* <https://doi.org/10.1038/s41409-022-01693-8>, published online 30 April 2022

The caption of Fig. 1 was corrected from “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemia-free survival (c, LFS), and overall survival(d, OS) patients receiving

post-transplant cyclophosphamide (PTCy) versus Cyclosporine A (CSA) / methotrexate (MTX)” to “Transplant outcomes. Non-relapse mortality (a, NRM), relapse incidence (b, RI), leukemia-free survival (c, LFS), and overall survival (d, OS) of patients receiving reduced intensity versus myeloablative conditioning regimen”. The original article has been corrected.